StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Abrysvo (bivalent RSV vaccine by Year

Abrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Abrysvo (bivalent RSV vaccine: $1,033M in FY2025, up 36.8% from a year earlier.

Latest, FY2025
1,033
Period ended Dec 31, 2025
Change on a year earlier
+36.8%
755 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| Abrysvo | 1,033 | 755 | 37% | 36% | 542 | 594 | (9%) | 491 | 160 | * | *”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAbrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,033+36.8%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024755-15.2%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 2023890–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20220–Form 10-K (filed 2025-02-27) ↗
FY2021Dec 31, 20210–Form 10-K (filed 2024-02-22) ↗

Breakdown

What makes up abrysvo (bivalent RSV vaccine

Cite this data

StockData. (2026). Pfizer Abrysvo (bivalent RSV vaccine ($M), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/abrysvo-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.